Baricitinib effectively regrows hair in severe alopecia areata cases.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
Matriptase-2 helps control iron levels by suppressing hepcidin, and its deficiency can cause iron-deficiency anemia.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
1 citations
,
November 2025 in “Neuro-Oncology” Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
November 2022 in “Journal of Investigative Dermatology” Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
25 citations
,
January 2011 in “Annals of Dermatology” Erlotinib can cause hair loss as a side effect.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
5 citations
,
February 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
November 2019 in “British Journal of Dermatology” FOL-005 peptide may help treat excessive hair growth safely.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
November 2025 in “Cancer Management and Research” Targeting Keratin 17 may help overcome cancer therapy resistance.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
21 citations
,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
Baricitinib is more effective than methotrexate for severe alopecia areata.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.